Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Longeveron Inc (NQ: LGVN )

1.870 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Longeveron Inc

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces Participation at Upcoming National Investment Banking Association Conference
Via Investor Brand Network
As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs
Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to experts, up to 80% of the population will experience back pain at some point. 
Via Benzinga
Earnings Scheduled For August 11, 2023
Companies Reporting Before The Bell • Consolidated Water Co (NASDAQ:CWCO) is estimated to report quarterly earnings at $0.22 per share on revenue of $30.27 million. 
Via Benzinga
Earnings Preview: Longeveron
Via Benzinga
LGVN Stock Earnings: Longeveron Misses EPS, Revenue Estimates
LGVN stock earnings show Longeveron reporting a wider loss than analysts expected and missing revenue estimates. 
Via InvestorPlace
Recap: Longeveron Q1 Earnings
Via Benzinga
Preview: Longeveron's Earnings
Via Benzinga
Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions
By David Willey, Benzinga 
Via TheNewswire.com
Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions
--News Direct-- 
Via News Direct
Longeveron – This Biotech Company Is Using The Body's Own Cells To Fight Age-Related Diseases
Wa'el Hashad, CEO of Longeveron (NASDAQ: LGVN), was recently interviewed by Benzinga. 
Via Benzinga
Longeveron Announces Key Additions To Its Leadership Team And Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions
Longeveron, Inc. (NASDAQ: LGVN) is a clinical-stage biopharmaceutical company focused on therapies for age-related and life-threatening diseases. 
Via Benzinga
Longeveron – Regenerative Medicine Developer Announces 100% Long Term Survival Rate For Children With HLHS
Hypoplastic left heart syndrome, or HLHS, has a historical mortality rate of 20% within five years of diagnosis. The disease affecting children may have a new therapy in Longeveron’s (NASDAQ: LGVN)... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron’s Lomecel-B Improve Outcomes?
HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron’s Lomecel-B Improve Outcomes? 
Via News Direct
Exposures Product Safety
HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron’s Lomecel-B Improve Outcomes?
By David Willey, Benzinga 
Via TheNewswire.com
Exposures Product Safety
HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron's Lomecel-B Improve Outcomes?
Longeveron (NASDAQ: LGVN) announced the results of its phase 1 trial for infants with a rare and serious congenital heart disease (CHD), known as hypoplastic left heart syndrome. 
Via Benzinga
Earnings Scheduled For May 12, 2023
Companies Reporting Before The Bell • Honda Motor Co (NYSE:HMC) is expected to report earnings for its fourth quarter. 
Via Benzinga
Longeveron's Lomecel-BTM Shows Encouraging Survival Data, Keeps Hypoplastic Left Heart Syndrome Pediatric Patients Heart Transplant-Free
Longeveron Inc (NASDAQ: LGVN) announced new long-term follow-up data from its ELPIS I trial of Lomecel-BTM for patients with  
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. 
Via Benzinga
Why Is Longeveron (LGVN) Stock Up 30% Today?
Longeveron (LGVN) stock is on the move Tuesday after releasing new long-term survival data from HLHS treatment Lomecel-B. 
Via InvestorPlace
Longeveron Doses First Patient In Phase 2 Clinical Trial Of Lomecel-B™ In Japan For Aging-Related Frailty
Longeveron Inc. (NASDAQ: LGVN) announced that the first patient has been treated with Lomecel-BTM in its Phase 2 clinical trial in patients with Aging-Related Frailty in Japan. The trial aims to enroll... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 74 companies achieved new lows for the year. 
Via Benzinga
Earnings Scheduled For March 10, 2023
Companies Reporting Before The Bell • CSI Compressco (NASDAQ:CCLP) is estimated to report earnings for its fourth quarter. • Longeveron (NASDAQ:LGVN) is expected to report earnings for its fourth... 
Via Benzinga
Insiders Just Bought $1 Million of This Deep Value Tech Stock
CEO and CFO buying is a bullish indicator... and based on new SEC filings, things are heating up for IHRT stock. Dive in here. 
Via InvestorPlace
3 Penny Stocks That Could Rise 500% in 2023
Tilt the odds in your favor in 2023 with some of these high-potential penny stocks. The risks are high, but so are the rewards. 
Via InvestorPlace
Longeveron Shares Surge Following FDA Decision on Biogen Alzheimer's Drug
Shares of Longeveron (NASDAQ: LGVN) are trading 5.37% higher amid strength in Alzheimer's-related stocks after the FDA granted accelerated approval to Biogen (NASDAQ: BIIB)'s Leqembi.  
Via Benzinga
Elon Musk Is a Genius Market Timer. That’s Bad News for Tesla (TSLA) Stock.
Elon Musk is great at timing the market. He's selling TSLA stock now, and savvy investors would be wise to follow suit. 
Via InvestorPlace
Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket
Gainers Netcapital Inc. (NASDAQ: NCPL) shares rose 91.3% to $2.65 in pre-market trading following Q2 results. Netcapital posted Q2 earnings of $0.04 per share on sales of $1.78 million. 
Via Benzinga
How to Find Stocks That Rise 10x
Investors looking for 10X stocks should prioritize companies in high-growth areas that demonstrate high earnings quality. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.